ENB Therapeutics Closes Series A Round of Funding

New York, NY, September 20, 2018: ENB Therapeutics Inc., a biopharmaceutical company pioneering pathways in endothelin-based oncologics, today announced that it has closed its Series A private equity financing. Proceeds from the financing will be used to advance the company’s lead investigational drug compound, ENB-003,a first-in-class, selective inhibitor of the endothelin B receptor (“ETBR”) through pre-clinical and early clinical development for the treatment of immunotherapy-resistant cancers. Remiges Ventures served as lead investor for the financing with participation from New York State Development, BioAdvance and Alexandria Ventures. “We are extremely gratified to have attracted a leading group of investors to complete our Series A financing who recognize the potential of ENB-003 to overcome resistance to immunotherapy across multiple tumor types and indications,” said Sumayah Jamal, Founder, President and Chief Scientific Officer of ENB. “We have already demonstrated robust pre-clinical efficacy in relevant mouse models across multiple resistant cancers and  a favorable safety profile. We now have the capital necessary to advance ENB-003 into Phase 1 clinical trials during the second half of 2019.” Taro Inaba, Managing Partner at Remiges, added, “We believe that ENB Therapeutics’ novel compounds have the potential to enhance the efficacy of immunotherapies and potentially prolong patient survival and thereby address the high unmet medical need which still exists despite the successful development and widespread use of immunotherapies. Therefore, we are very pleased to have the opportunity to support the continued clinical development of ENB-003, which could improve the lives of patients with cancer.”   About ENB Therapeutics ENB Therapeutics is a biopharmaceutical company pioneering the development of selective inhibitors of the endothelin B receptor (“ETBR”) to reverse...

ENB to present at 2016 Pitch Fest organized by New York Bio

ENB was selected as one of 33 companies to present at this year’s Pitch Fest on May 11th, at the New York Bio Annual Conference. The conference is being held at NYC’s Time Warner Center. Representative entrepreneurs  will give a 15-minute pitch to a panel of judges made up of investors and other experts. This will be followed by 5 minutes of Q&A and 5 minutes of non-rebuttal feedback from the panel. Pitches will be evaluated and scored on a range of important business and scientific criteria. Leading scorers and winners will be announced during the keynote program later in the day. Judges for this year’s pitch fest hail from Merck, Sanofi, Pfizer, J&J, Lilly, leading VC law and accounting, and many...

ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC

April, 2016 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels (www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals. ENB’s investor presentation was one of 3 chosen for the event. ENB’s CSO Dr. Sumayah Jamal gave the presentation and was voted by an audience of over 100 as “Best-in-Show”. ENB is now qualified to advance to the  annual “Best of the Best/People’s Choice”...

ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC

March, 2016 ENB Therapeutics presents poster entitled “Development of ENB-001 for the Treatment of Melanoma Brain Metastasis” at the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Meeting in NYC. The meeting draws more than 250 colleagues and renowned speakers with a program designed for oncologists, dermatologists, researchers and students. The poster abstract is below: As systemic therapy improves, patients with melanoma are living longer. As a result, 44% – 76% of all those diagnosed with advanced melanoma are developing, and dying from, melanoma that metastasizes to the central nervous system (CNS), specifically the brain. This catastrophic event is the most common cause of death in patients with melanoma and there are no approved therapies specifically for melanoma with CNS involvement. A common cause of resistance to melanoma treatment is upregulation of the endothelin B receptor (ETBR). ENB-001 is a small molecule that precisely targets the ETBR, inhibiting downstream RAF, MEK and AKT activity. ENB-001 has achieved proof of concept in animal models of CNS melanoma as well as extra-CNS melanoma metastases. Efficacy in preclinical studies for glioblastoma and squamous cell carcinoma has also been demonstrated. ENB-001, in contrast to approved MEK inhibitors, also has immunostimulatory effects, enhancing T-cell homing and adhesion to cancer cell vasculature. We have partnered with a drug formulation company that has a proprietary nanoparticle intranasal delivery system that bypasses the blood brain barrier, and will be used to deliver ENB-001 directly to the central nervous system. The development of ENB-001 will have a significant impact for patients with CNS melanoma. Further opportunities include the treatment of non-CNS melanoma metastatic disease, other malignancies, and the development of...

ENB’s Co-founder and CSO Dr. Sumayah Jamal is accepted into the 2016 Pharma Class of Springboard Health Innovation Hub

March 2016 Sumayah Jamal, MD-PhD, Co-founder and CSO of ENB was accepted into the 2016 Pharma Class of the Springboard Health Innovation Hub. Springboard’s highly competitive Health Innovation Hub is a year-long program for women-led healthcare and life science companies seeking seed and growth funding to fuel expansion and product development. Companies selected for the Pharma track will be matched with a team of relevant, targeted advisors and participate in several in-person and virtual workshops and presentation sessions throughout the year that provide exposure to influencers, active investors, and potential strategic partners. Springboard vetted companies have an impressive 83% funding rate and have raised almost $7B since the program’s inception 15 years ago. ENB is honored to have been chosen as a Springboard...